Form 4 for DXCM Dexcom
Accepted 2026-05-27 16:39:16 ET · period of report 2026-05-22 · accession 0001093557-26-000099 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-27 16:39 | 2026-05-22 | DXCM | Leach Jacob Steven | Pres, CEO, Dir | F - Tax | $71.90 | -1,451 | 420.4K | -0.3% | -$104.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-22 | F | D | 1,451 | $71.90 | 420,359 | D | — | — | (F1) Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person. (F2) Included in this number are 145,686 unvested restricted stock units, 104,516 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027. |